Cargando…
Pidotimod: In-depth review of current evidence
Pidotimod, an immunostimulant, is researched for over two decades. Current evidence indicates its utility in a variety of indications in children as well as in adults. Its immunostimulant activity has been firmly established in the management of recurrent respiratory infections in children with or w...
Autores principales: | Mahashur, Ashok, Thomas, PK, Mehta, Parthiv, Nivangune, Kundan, Muchhala, Snehal, Jain, Rishi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710962/ https://www.ncbi.nlm.nih.gov/pubmed/31464215 http://dx.doi.org/10.4103/lungindia.lungindia_39_19 |
Ejemplares similares
-
Pidotimod: the state of art
por: Ferrario, Beatrice E, et al.
Publicado: (2015) -
Pidotimod: the past and the present
por: Zuccotti, Gian Vincenzo, et al.
Publicado: (2013) -
Immunostimulants in respiratory diseases: focus on Pidotimod
por: Puggioni, Francesca, et al.
Publicado: (2019) -
Pidotimod in the treatment of pediatric recurrent respiratory tract infection
por: Li, Xia, et al.
Publicado: (2019) -
Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients
por: Ucciferri, Claudio, et al.
Publicado: (2020)